She and her colleagues at inThought Research recently published a report summarizing the brain shuttle technology research landscape in the biotech sector.

Menlo Ventures Partner, and co-author of the report, Derek Xiao talks about how AI is improving the P&L of health systems and helping with staffing shortages. Medical documentation, billing and scribing are the biggest areas of adoption today, while patient engagement and the post acute relationship are emerging as next to be impacted.

CEO Frédéric Legros walks us through the science and explains why he believes ARTHEx has a unique approach compared to others we have seen in the field. The company raised an $87M series B in September.

CEO Robert Jacks describes the history of learning about how Sparrow's asset lowered cortisol in Cushing's syndrome, and new data suggesting that doing so could be beneficial for treatment-resistant T2D patients.

CEO Hugo Fry describes the scientific idea behind antigenic tolerization, and discusses Topas' recent PoC data that was presented at Digestive Disease Week.

He explains the story of this enzyme and the biology of how CTPS1 and CTPS2 interact. Step is in the clinic in lymphoma and solid tumors, and recently raised a €38 series C.

CEO Jordi Fàbrega and CFO Josep Prous discusses the asset, CTH120, which is a NCE and proprietary to Connecta.

CEO Jean Marie Duvall describes the company's programs, one focused on male inferitliy and another that may have dual purposes of helping with embryo implantation and adenomyosis. She says to make sure there is a clear commercial path if when you focus on this field.

CEO Birgit Zech and CSO Edward Holson discuss the unique beginning of the company (a powerpoint deck), and the difficulties in drugging phosphatases. Plus, the company is now disclosing two indications/targets in development.

CEO Antti Vuolanto walks us through recent phase 1b data, which reported safety and PK data. Biomarker data will be forthcoming before the end of the year.